SCHEMBL19933385

SCHEMBL19933385

Bc1nc(C(=O)NCC(=O)O)c(O)c(B)c1-c1cccc(F)c1

nearest known ligand 0.58

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 20/20 0.58
FTO Q9C0B1 3/20 0.44
BBOX1 O75936 2/20 0.44
KDM5B Q9UGL1 1/20 0.44
KDM2A Q9Y2K7 1/20 0.44
EGLN3 Q9H6Z9 2/20 0.44
TET3 O43151 1/20 0.44
VEGFA P15692 1/20 0.44
FLT1 P17948 1/20 0.44
ASPH Q12797 1/20 0.44
TET2 Q6N021 1/20 0.44
KDM8 Q8N371 1/20 0.44
OGFOD1 Q8N543 1/20 0.44
TET1 Q8NFU7 1/20 0.44
HIF1AN Q9NWT6 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19933384 0.86 EGLN1 (0.57) EGLN1FTOBBOX1KDM5BKDM2A
SCHEMBL19933404 0.84 EGLN1 (0.60) EGLN1FTOBBOX1KDM5BKDM2A
SCHEMBL19933488 0.81 EGLN1 (0.67) EGLN1FTOBBOX1EGLN3TET3
SCHEMBL19933493 0.81 EGLN1 (0.66) EGLN1FTOBBOX1KDM5BKDM2A
SCHEMBL19933380 0.78 EGLN1 (0.49) EGLN1FTOBBOX1KDM5BKDM2A
SCHEMBL19933510 0.76 EGLN1 (0.43) EGLN1FTOBBOX1KDM5BKDM2A
SCHEMBL3484399 0.74 EGLN1 (1.00) EGLN1FTOBBOX1EGLN3TET3
SCHEMBL30145054 0.74 EGLN1 (1.00) EGLN1FTOBBOX1EGLN3TET3
SCHEMBL28789349 0.74 EGLN1 (0.66) EGLN1FTOBBOX1KDM5BKDM2A
SCHEMBL29721591 0.74 EGLN1 (0.66) EGLN1FTOBBOX1KDM5BKDM2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180065933-A1 DEUTERIUM-ENRICHED HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE ENZYME INHIBITORS AKEBIA THERAPEUTICS, INC. (US) 2018-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180065933-A1 DEUTERIUM-ENRICHED HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE ENZYME INHIBITORS HIF1AN, EGLN3, EGLN2 EGLN1 6/4885FTO 971/4885BBOX1 289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.